UCB receives not-approvable letter from US FDA for lacosamide.
KeywordsMarketing Neuropathic Pain Medium Release Lacosamide Marketing Approval
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
© Adis International Ltd 2008